Clinical Trial Update: Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating Brentuximab Vedotin with Gemcitabine for younger patients with relapsed or refractory Hodgkin lymphoma completed, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-01